Screener
Pelthos Therapeutics PTHS License — Interest accretion
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Pelthos Therapeutics in its filing.
Tagged under the XBRL concept pths:ContractualObligationLiabilityInterestAccretion.
The source filing: Pelthos Therapeutics’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 7:06 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001919246-26-000070
| Line item | Reedy Creek Purchase Agreement | ZELSUVMI Royalty Agreement | Xepi Royalty Agreement | Sato Payments | Total |
|---|---|---|---|---|---|
| Carrying value at December 31, 2025 | $20,871 | $9,773 | $2,220 | $1,127 | $33,991 |
| Interest accretion | 781 | 588 | 55 | 27 | 1,451 |
| Royalty payments accrued | (214) | (160) | — | — | (374) |
| Carrying value at March 31, 2026 | 21,438 | 10,201 | 2,275 | 1,154 | 35,068 |
| Less: current portion | 1,731 | 1,400 | 156 | 116 | 3,403 |
| Convertible fees allocated to royalty | — | — | 64 | 33 | 97 |
| Carrying value at March 31, 2026, net of current portion | $19,707 | $8,801 | $2,055 | $1,005 | $31,568 |
| March 31, 2026 Effective Annual Discount Rate | 14.8% | 23.7% | 9.8% | 9.7% |
Item 1. Financial Statements (unaudited)
FAQ
- What is Pelthos Therapeutics's license — interest accretion?
- Pelthos Therapeutics (PTHS) reported license — interest accretion of $1.45M in Q1 2026.
- What does license — interest accretion mean?
- Reflects the periodic increase in the carrying value of a long-term licensing liability due to the passage of time, typically calculated using an imputed interest rate. This represents the non-cash financing cost associated with deferred payment obligations for acquired intellectual property.
Ask your AI about Pelthos Therapeutics's license — interest accretion.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude